Bionano (BNGO) Q3 2026 earnings review
Bionano's test kit sales hit a record, but cash shrinks
Bionano, which sells DNA-imaging machines and test kits to genetics labs, shipped a record number of test kits while its cash reserves shrank further. Third-quarter revenue rose 12% from a year ago, driven by a 24% increase in disposable consumables, and lower overhead costs narrowed the operating loss. Interim chief executive Al Luderer held the full-year outlook steady, which by our math leaves fourth-quarter revenue growing about 12% at the middle of the range.
| Revenue | $8.3M +12% from a year ago |
|---|---|
| Flowcells sold | 9,870 +18% from a year ago |
| Gross margin | 48% 53% last quarter |
| Full-year revenue outlook | Unchanged middle of the range: 12.2% growth |
⚖️ Verdict: 🔴 Bearish
The story got worse because cash fell to $8.7 million and gross margin gave back five percentage points of its recent gains. A jump in service costs pulled gross margin down from last quarter's record, while higher customer receivables and inventory tied up cash even as the company sold new shares. On the positive side, flowcell volume hit a new high of 9,870 units.
The question now is whether Bionano can clear its factory backorder and lift fourth-quarter sales before it has to raise capital on difficult terms. Either rising test-kit volume and lower overhead ease the cash squeeze, or slow collections and a wide full-year outlook range force a near-term financing. Fourth-quarter cash and flowcell shipments will tell.
🐂 Bull Case
Record Flowcell Volume Carries Top-Line Growth
Bionano sells optical genome mapping (OGM) machines that image long strands of DNA, along with disposable nanochannel array flowcells that hold the DNA during each test. Because laboratories must buy a new flowcell for every sample they run, flowcell volume measures how often customers actually use their machines.
The genomics company sold a record 9,870 flowcells this quarter, up 18% from a year ago and 7% above last quarter's record. Consumables revenue rose 24% from a year ago to $4.7 million, or about $476 per flowcell by our math. Interim chief executive Al Luderer said cancer centers are bringing OGM into clinical labs, "expanding the base of routine users that drives utilization of our products." Outside consumables, revenue stayed flat at $3.6 million by our math, so disposable test kits carried the entire top-line increase.
What to watch: fourth-quarter flowcell volume when Bionano reports full-year results. A step above 10,000 units would show that factory output is catching up with laboratory demand.
Lower Overhead Costs Narrowed the Operating Loss
Bionano has spent the past two years cutting its sales and administrative overhead to keep the business running on a smaller budget. Those cuts continued to shrink its quarterly losses even as research spending crept higher.
- Selling, general and administrative expense: $7.4 million, down 33.1 percentage points of revenue from a year ago
- Research and development expense: $3.0 million, down 1.9 percentage points of revenue from a year ago
- Operating expenses excluding one-offs: $8.8 million, down 9% from $9.7 million a year ago
- Operating loss: $6.5 million, narrowed by 23% from $8.5 million a year ago
Lower overhead matters because the diagnostics provider still spends almost twice as much as it earns in gross profit. Trimming sales and administrative costs by $1.6 million from a year ago did all the work in reducing the operating loss.
What to watch: fourth-quarter operating expenses excluding one-offs. Holding that line below $8.8 million would show management can contain costs while launching its updated sample-preparation products.
Positives this quarter didn't test
Two standing drivers from earlier in the year got qualitative support in the release, but their exact numbers await the quarterly filing.
- Insurance and regulatory coverage: Bionano announced three independent myeloid cancer studies and state-level approvals for third-party OGM tests, which Luderer said built a "clearer reimbursement pathway for OGM-based testing"; the filing's geographic table will show whether US clinical sales grew.
- European clinical adoption and routine-user mix: EMEA generated 59% of revenue last quarter and existing customers bought 96% of flowcells; the filing's segment notes will show whether existing European labs drove this quarter's 9,870 flowcells.
🐻 Bear Case
Cash Fell to $8.7 Million Despite New Share Sales
Bionano warned in its risk disclosures that continuing as a going concern requires it to "manage costs and obtain significant additional financing". The balance sheet shows why that warning remains the central problem for the business.
Total cash, investments, and restricted cash fell from $10.4 million in June to $8.7 million in September, and only $8.2 million of that is unrestricted. Meanwhile, additional paid-in capital on the balance sheet rose by $3.1 million. After subtracting $0.3 million of stock-based compensation, the company raised about $2.8 million from equity issuances by our math. Without that new money, Bionano burned about $4.5 million of cash in the quarter by our math, leaving less than two quarters of cash at that pace.
What to watch: the liquidity footnote and subsequent-events section in the third-quarter 10-Q filing. Without a financing of at least $10 million, cash will run low early in 2027.
Growth Slowed Instead of Accelerating
"Our third quarter results reflect the momentum building across our business and the broader genomics community, further accelerating the adoption of optical genome mapping (OGM) in clinical and commercial settings," interim chief executive Al Luderer said.
The numbers in the release show a slowdown instead. Total revenue growth cooled from 21% in the second quarter to 12% in the third, and sequential revenue edged up just 1.3% to $8.28 million. That landed inside the $8.2–8.6 million outlook range, but 1.5% below the $8.4 million middle of the range — the first time in eight quarters Bionano finished below its own midpoint. Flowcell volume growth also stepped down from 27% to 18%, and Consumables revenue growth slowed from 31% to 24%.
What to watch: fourth-quarter revenue against the $8.87 million implied by the middle of the full-year outlook. Landing near the $7.87 million bottom of the implied range would mean year-over-year growth disappeared entirely.
Service Costs Pulled Gross Margin Down Five Points
Rising gross margin had been one of Bionano's clearest improvements, climbing from 42% in late 2024 to a record 53% last quarter. In the third quarter that progress reversed, as gross margin excluding one-offs dropped five percentage points to 48%, even though higher-margin consumables grew to 57% of total revenue.
The culprit was cost of service and other revenue — the expense of running diagnostic tests and maintaining customer equipment. That cost jumped from $133 thousand in the second quarter to $639 thousand in the third, rising 6.1 percentage points of total revenue by our math (and up 5.6 points from a year ago). Cost of product revenue fell 1.0 percentage point of revenue from last quarter, so service costs more than wiped out the benefit of selling more flowcells.
What to watch: cost of service and other revenue in the fourth quarter. A second quarter above $450 thousand of service costs on similar service revenue would confirm a structural drag on gross margin.
Risks this quarter didn't answer
Four standing concerns could not be read from the earnings release and depend on the conference call or the 10-Q filing.
- US revenue decline: US sales fell 28% from a year ago in the second quarter despite higher Medicare payment rates for OGM tests; the 10-Q geographic footnote will show whether US demand stabilized.
- Flowcell manufacturing backorder: management previously said factory supply would catch up with customer demand by mid-to-late fourth quarter; fourth-quarter shipments will test that schedule.
- Executive leadership gaps: Al Luderer remains interim chief executive for a third quarter and the release names no chief financial officer; any permanent appointment would address the vacancy.
- Customer concentration: about 130 routine-use labs generated 83% of consumables revenue last year; annual disclosures in the 10-K will show whether the user base broadened.
💲 Other KPIs
Uncollected customer bills jumped 34.1% from last quarter and 29.3% from a year ago, far outpacing the 1.3% quarterly and 12.3% yearly growth in revenue. After falling in the first quarter and rising modestly in the second, that buildup tied up $1.49 million of cash during the third quarter.
Stock on hand rose 25.2% from last quarter (or $1.31 million), reversing three straight quarters of flat-to-slightly-lower inventory between late 2025 and mid-2026. Building stock ahead of the fourth quarter absorbed cash now, though it may help the company clear its flowcell backorder.
Total contract liabilities — cash customers have paid upfront for extended warranties, support, and software not yet delivered — fell 11.4% from a year ago and 3.8% from last quarter by our math. The balance has shrunk slightly for three consecutive quarters.
🔮 Guidance
Unchanged. The full-year plan still calls for $31 million to $33 million of revenue, or 12.2% growth at the $32 million middle of the range. By our math, that leaves $7.87 million to $9.87 million for the fourth quarter — 11.5% growth at the middle ($8.87 million), but a 1.1% decline at the bottom against a supply-constrained fourth quarter last year. Management raised the bottom of this range by $1 million last quarter after holding it in the first.
❓ Key Questions
Why did service costs jump to $639 thousand this quarter?
Cost of service and other revenue more than quadrupled from $133 thousand in the second quarter, while service revenue dipped slightly to $449 thousand. That swing pulled gross margin down five percentage points from last quarter's 53% record.
How will Bionano fund operations past early 2027?
Total cash and investments dropped to $8.7 million ($8.2 million unrestricted), and the company burned about $4.5 million before equity sales in the third quarter by our math. At that rate, existing cash covers less than two quarters.
Did US revenue stop falling in the third quarter?
US sales dropped 28% from a year ago in the second quarter even after higher Medicare payment rates took effect in January. The release does not disclose regional revenue, leaving it unclear whether US clinical labs are ordering more.
Has the flowcell manufacturing backorder cleared?
Management previously targeted the middle-to-end of the fourth quarter to catch up on backordered flowcells. Because the full-year outlook still allows for a slight fourth-quarter revenue drop at the low end, investors need to know whether supply still caps shipments.